Learning Outcomes:
Students will be expected to:
To be able to describe the primary components of a standard cost-effectiveness analysis including cost-effectiveness ratios and the use of cost-effectiveness thresholds;
To be able to explain the rationale for conducting a cost-effectiveness analysis and the reasons why the application of cost-effectiveness analysis is contentious;
To combine technical understanding of CEA methods with insight regarding a pragmatic understanding of policy formulation to explain why the impact of CEA on healthcare services may appear modest;
To explain how cost-effectiveness analysis departs from conventional economic analysis;
The ability to present a critique of a published cost-effectiveness analysis, identifying points of strength and areas for improvement.
Indicative Module Content:
The lecture course follows this outline:
1. Introduction- Market Failure in Health; Healthcare expenditure; Rationale for HTA HEE. Types of HEA
2. Health Related Quality of Life (HRQoL) estimation, standard gamble and time trade off, QALYs and limitations including insensitivity
3. Costs and their estimation, the choice of perspective and discounting
4. Modelling approaches, CE planes, ICERs, net benefit and decision rules
5. Cost-effectiveness thresholds, theory and practice, implementation in Ireland
6. CEA processes in Ireland; threshold II: supply side vs demand side thresholds
7. Uncertainty analysis with CEA, one way sensitivity analysis, probability sensitivity analysis and expected value of information
8. Theoretical foundations of CEA the departure from conventional economic theory
9. Prioritisation within policy frameworks: specific thresholds, The UK Cancer Drugs Fund, QALY weighting, discounting adjustments, shortfall mechanisms
10. Equity weighting in CEA: applying the Cookson framework: In class presentations of critical appraisal of a published CEA
11. Application of CEA to cancer screening: common errors in strategy selection, comparison and cost-effectiveness estimate reporting